RxDoctor Payments Data

Ashley McGuire, DO

Family Medicine · Abingdon, VANPI 1114151446

Payments from drug & device makers

$998in general payments, 2019–2025

Across 64 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$276
  • Novo Nordisk$122
  • Novartis$117
  • Amgen$106
  • AstraZeneca$67
  • Astellas Pharma US Inc$50
  • plus $260 from 11 others

What the payments were for

  • Food & beverage$998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$998 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$17,939
Medicare patients
57
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$72,926
JanuviaSitagliptin Phosphate70$67,215
EliquisApixaban65$57,985
JardianceEmpagliflozin59$55,113
XareltoRivaroxaban19$22,730
FarxigaDapagliflozin Propanediol32$20,779
TrulicityDulaglutide15$16,600
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,779
MyrbetriqMirabegron12$10,525
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$10,046
Spiriva RespimatTiotropium Bromide11$7,648
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$6,901
TradjentaLinagliptin12$6,166
AprisoMesalamine11$5,650
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$122$72,92672 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$46$68,92782 claims
MerckJanuvia$23$67,21570 claims
PfizerEliquis$14$57,98565 claims
AstraZenecaFarxiga$67$20,77932 claims
GSKTrelegy Ellipta, Anoro Ellipta$25$20,00026 claims
Astellas Pharma US IncMyrbetriq$50$10,52512 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCApriso$29$5,65011 claims
AbbVieSynthroid$276$1,12124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →